logo
Twitter
Discord
Email
logo
Masimo Corporation

Masimo Corporation

NASDAQ•MASI
CEO: Ms. Michelle M. Brennan
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2007-08-08
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Contact Information
52 Discovery, Irvine, CA, 92618, United States
949-297-7000
www.masimo.com
Market Cap
$7.65B
P/E (TTM)
-13.4
79.7
Dividend Yield
--
52W High
$194.88
52W Low
$133.70
52W Range
13%
Rank35Top 21.9%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$371.50M-26.38%
4-Quarter Trend

EPS

-$1.86-1133.33%
4-Quarter Trend

FCF

$50.90M-1182.98%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Healthcare Revenue Growth Nine-month revenue reached $1.11B, up 8.5%, driven primarily by increased capital equipment sales volume.
Gross Margin Expansion Gross profit $697.9M, up 11.5% for nine months; margin improved to 62.6% despite $7.2M tariff impact.
Operating Income Surge Operating income $226.1M for nine months, showing strong profitability improvement compared to $133.3M prior period.
Strengthened Cash Position Cash and equivalents $312.3M as of September 27, 2025, significantly increased from $123.6M at year-end 2024.

Risk Factors

Discontinued Operations Loss Total net loss $(219.8M) driven by $(365.6M) loss from discontinued non-healthcare business sale adjustments.
Tariff Cost Headwinds Incremental tariffs cost $7.2M over nine months, partially offsetting gross profit gains and impacting Cost of Goods Sold.
Material Litigation Exposure Material litigation risk persists regarding Apple patent infringement claims; jury trial scheduled to begin November 4, 2025.
Customer Concentration Risk Concentration risk noted; one just-in-time distributor accounted for 18.8% of healthcare revenue for the nine months.

Outlook

Profitability Strategic Focus Strategic realignment initiated in Q4 2024 focuses on profitability and maximizing return on invested capital going forward.
Adequate Liquidity Forecast Cash $312.3M plus $140.9M available borrowing capacity provides adequate resources for next twelve months operations.
New Executive Leadership New CEO Catherine Szyman appointed effective February 12, 2025, driving strategy and operational execution.
Assessing Tax Legislation Currently assessing the impact of recently enacted One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.

Peer Comparison

Revenue (TTM)

Grifols, S.A.GRFS
$8.30B
+7.3%
Jazz Pharmaceuticals plcJAZZ
$4.16B
+4.1%
Charles River Laboratories International, Inc.CRL
$4.02B
-0.9%

Gross Margin (Latest Quarter)

Jazz Pharmaceuticals plcJAZZ
77.1%
-12.3pp
Guardant Health, Inc.GH
64.7%
+3.6pp
Masimo CorporationMASI
62.1%
+9.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
GH$12.67B-31.9151.9%101.8%
GMED$12.19B28.910.0%2.3%
JAZZ$10.31B-28.0-9.3%9.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-14.8%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 24, 2026
|
EPS:$1.39
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 27, 2025|Filed: Nov 4, 2025|
    Revenue: $371.50M-26.4%
    |
    EPS: $-1.86-1133.3%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 28, 2025|Filed: Aug 5, 2025|
    Revenue: $370.90M+7.9%
    |
    EPS: $0.95+216.7%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 29, 2025|Filed: May 6, 2025|
    Revenue: $372.00M+9.5%
    |
    EPS: $-3.17-980.6%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 28, 2024|Filed: Feb 25, 2025|
    Revenue: $2.09B+2.3%
    |
    EPS: $-5.72-471.4%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 28, 2024|Filed: Nov 6, 2024|
    Revenue: $504.60M+5.4%
    |
    EPS: $0.18-10.0%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 29, 2024|Filed: Aug 7, 2024|
    Revenue: $343.90M-24.5%
    |
    EPS: $0.30+0.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 30, 2024|Filed: May 7, 2024|
    Revenue: $339.60M-39.9%
    |
    EPS: $0.36-10.0%
    Miss
  • Form 10-K/A - FY 2023

    Period End: Dec 30, 2023|Filed: Apr 29, 2024|
    Revenue: $2.05B+0.6%
    |
    EPS: $1.54-42.5%
    Beat